Cidara Therapeutics

Cidara Therapeutics' Mission

Cidara Therapeutics focuses on developing targeted immunotherapies to save lives and enhance the standard of care for patients battling serious diseases. Recognizing the critical need for advanced medical interventions, Cidara leverages cutting-edge technology to address unmet medical needs, particularly in infectious diseases and immuno-oncology. The company's mission underscores a commitment to innovation and patient-centric solutions, aiming to transform the therapeutic landscape with novel treatments.

Cidara Therapeutics' Cloudbreak Platform

Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs). This platform is pioneering in creating 'single molecule cocktails' by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The DFCs are designed to inhibit specific disease targets while simultaneously engaging the immune system, offering a dual mechanism of action that enhances therapeutic efficacy. The Cloudbreak platform represents a significant advancement in the field of immunotherapy, enabling the development of versatile and potent treatments for a range of diseases.

Cidara Therapeutics' CD388

One of the flagship developments from Cidara Therapeutics is CD388, a drug-Fc conjugate (DFC) aimed at the universal prevention of seasonal and pandemic influenza with a single dose. CD388 is currently in Phase 2 clinical trials, targeting the prevention of seasonal influenza A and B. This innovative approach seeks to provide a long-lasting and comprehensive solution to flu prevention, potentially transforming how influenza is managed globally. The success of CD388 could significantly reduce the burden of seasonal flu and increase preparedness for future pandemics.

Cidara Therapeutics' Headquarters

Cidara Therapeutics is headquartered in San Diego, California, a hub for biotechnology and life sciences innovation. The strategic location provides access to a wealth of scientific talent, research facilities, and industry partnerships. San Diego's vibrant biotech ecosystem supports Cidara's mission to advance groundbreaking therapies. The headquarters serves as the central hub for the company's research and development activities, fostering collaboration and innovation in the pursuit of life-saving treatments.

Cidara Therapeutics' Research and Development Programs

Beyond its work on influenza, Cidara Therapeutics is advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases. These initiatives leverage the company's Cloudbreak platform to develop novel immunotherapies that can address various serious health conditions. By targeting specific disease mechanisms and engaging the immune system, Cidara aims to create treatments that are both highly effective and safe. The ongoing R&D efforts highlight the company's commitment to expanding its therapeutic portfolio and addressing a broader range of medical needs.